



Docket No. 78-0116

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Civelli, Olivier, et al.	RESPONSE UNDER 37 CFR 1.116 <u>EXPEDITED PROCEDURE</u>
		Customer No.: 41552
Appl. No.:	09/932,161	Confirmation No.: 5376
Filed:	August 17, 2001	Group Art Unit: 1647
		Examiner: R. DeBerry
Title: SCREENING AND THERAPEUTIC METHODS FOR PROMOTING WAKEFULNESS AND SLEEP		

CERTIFICATE OF MAILING BY EXPRESS MAIL (37 CFR § 1.10)

"Express Mail" Mailing Label Number EV 540267544 US

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Sept. 1, 2004.

*Cris Johnson*  
Cris Johnson

**RESPONSE TO OFFICE ACTION**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Responsive to the Office Action mailed June 9, 2004, entry of the following amendments and remarks is respectfully requested.

Amendments to the claims are reflected in the listing of "Current Status of Claims" that begins of page 2 of this paper.

Remarks begin on page 4 of this paper.

CURRENT STATUS OF ALL CLAIMS

1-10. Canceled.

1 ~~N~~. (Previously amended) A method of screening for a compound for promoting wakefulness in a mammal, comprising:

(a) contacting a PrRP receptor with one or more candidate compounds under conditions wherein PrRP promotes interaction of PrRP receptor with an AMPA receptor associated protein;

(b) identifying a compound that promotes said interaction;

(c) providing said compound, and

(d) determining the ability of said compound to promote wakefulness.

2 ~~12~~. (Original) The method of claim ~~N~~, wherein said AMPA receptor associated protein is selected from the group consisting of GRIP, GRIP2 and PICK1.

13-40 (Canceled).

3 ~~41~~. (Previously Presented) The method of claim ~~N~~, wherein the ability of said compound to promote wakefulness is determined by a method selected from the group consisting of EEG measurement, EMG measurement and wake time measurement.

Serial No.: 09/932,161

~~4~~ 42. (Previously Presented) The method of claim ~~11~~, wherein the ability of said compound to promote wakefulness is determined by administering said compound to a mammal selected from the group consisting of a human, a non-human primate, a rat and a mouse.